195 related articles for article (PubMed ID: 24922544)
1. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate.
Song Y; Lin X; Kang D; Li X; Zhan P; Liu X; Zhang Q
Eur J Med Chem; 2014 Jul; 82():293-307. PubMed ID: 24922544
[TBL] [Abstract][Full Text] [Related]
2. Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.
Capasso A; Cerchia C; Di Giovanni C; Granato G; Albano F; Romano S; De Vendittis E; Ruocco MR; Lavecchia A
Oncotarget; 2015 Nov; 6(37):40202-22. PubMed ID: 26474275
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
4. A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death.
Bana E; Sibille E; Valente S; Cerella C; Chaimbault P; Kirsch G; Dicato M; Diederich M; Bagrel D
Mol Carcinog; 2015 Mar; 54(3):229-41. PubMed ID: 24155226
[TBL] [Abstract][Full Text] [Related]
5. SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.
Xia Y; Lei Q; Zhu Y; Ye T; Wang N; Li G; Shi X; Liu Y; Shao B; Yin T; Zhao L; Wu W; Song X; Xiong Y; Wei Y; Yu L
Cancer Lett; 2014 Dec; 355(2):297-309. PubMed ID: 25301449
[TBL] [Abstract][Full Text] [Related]
6. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
7. Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries.
Jing L; Wu G; Hao X; Olotu FA; Kang D; Chen CH; Lee KH; Soliman MES; Liu X; Song Y; Zhan P
Eur J Med Chem; 2019 Dec; 183():111696. PubMed ID: 31541869
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel 2,3-dihydrochromeno[3,4-d]imidazol-4(1H)-one derivatives as potent anticancer cell proliferation and migration agents.
Han X; Luo J; Wu F; Hou X; Yan G; Zhou M; Zhang M; Pu C; Li R
Eur J Med Chem; 2016 May; 114():232-43. PubMed ID: 26994691
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.
Lavecchia A; Di Giovanni C; Pesapane A; Montuori N; Ragno P; Martucci NM; Masullo M; De Vendittis E; Novellino E
J Med Chem; 2012 May; 55(9):4142-58. PubMed ID: 22524450
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.
Wang XM; Xu J; Li YP; Li H; Jiang CS; Yang GD; Lu SM; Zhang SQ
Eur J Med Chem; 2013 Sep; 67():243-51. PubMed ID: 23871904
[TBL] [Abstract][Full Text] [Related]
11. Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells.
Brault L; Bagrel D
Life Sci; 2008 Jan; 82(5-6):315-23. PubMed ID: 18191419
[TBL] [Abstract][Full Text] [Related]
12. A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
Brezak MC; Quaranta M; Mondésert O; Galcera MO; Lavergne O; Alby F; Cazales M; Baldin V; Thurieau C; Harnett J; Lanco C; Kasprzyk PG; Prevost GP; Ducommun B
Cancer Res; 2004 May; 64(9):3320-5. PubMed ID: 15126376
[TBL] [Abstract][Full Text] [Related]
13. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis.
Kar S; Wang M; Carr BI
Cancer Chemother Pharmacol; 2008 Oct; 62(5):831-40. PubMed ID: 18246350
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of selenazolopyridine derivatives with capability to induce apoptosis in human breast carcinoma MCF-7 cells through scavenge of intracellular ROS.
Zhou M; Ji S; Wu Z; Li Y; Zheng W; Zhou H; Chen T
Eur J Med Chem; 2015; 96():92-7. PubMed ID: 25874334
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries.
Tao Y; Hao X; Jing L; Sun L; Cherukupalli S; Liu S; Wu G; Xu S; Zhang X; Shi X; Song Y; Liu X; Zhan P
Bioorg Chem; 2021 Oct; 115():105254. PubMed ID: 34426152
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effect of natural tetrasulfides in human breast cancer cells is mediated through the inhibition of the cell division cycle 25 phosphatases.
Viry E; Anwar A; Kirsch G; Jacob C; Diederich M; Bagrel D
Int J Oncol; 2011 Apr; 38(4):1103-11. PubMed ID: 21253673
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
Wang G; Li C; He L; Lei K; Wang F; Pu Y; Yang Z; Cao D; Ma L; Chen J; Sang Y; Liang X; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2014 Apr; 22(7):2060-79. PubMed ID: 24629450
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.
Lavecchia A; Di Giovanni C; Novellino E
Expert Opin Ther Pat; 2010 Mar; 20(3):405-25. PubMed ID: 20166845
[TBL] [Abstract][Full Text] [Related]
19. Combination of 2-methoxy-3-phenylsulfonylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents.
Li H; Wang XM; Wang J; Shao T; Li YP; Mei QB; Lu SM; Zhang SQ
Bioorg Med Chem; 2014 Jul; 22(14):3739-48. PubMed ID: 24878359
[TBL] [Abstract][Full Text] [Related]
20. Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK.
Kar S; Wang M; Ham SW; Carr BI
Biochem Pharmacol; 2006 Nov; 72(10):1217-27. PubMed ID: 16930563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
